| Literature DB >> 29921756 |
Yuri Campelo1,2,3, Alicia Ombredane4, Andreanne G Vasconcelos5, Lucas Albuquerque6, Daniel C Moreira7, Alexandra Plácido8, Jefferson Rocha9, Harold Hilarion Fokoue10, Lydia Yamaguchi11, Ana Mafud12, Yvonne P Mascarenhas13, Cristina Delerue-Matos14, Tatiana Borges15, Graziella A Joanitti16, Daniel Arcanjo17, Massuo J Kato18, Selma A S Kuckelhaus19, Marcos P N Silva20, Josué de Moraes21, José Roberto S A Leite22,23.
Abstract
Schistosomiasis, caused by helminth flatworms of the genus Schistosoma, is an infectious disease mainly associated with poverty that affects millions of people worldwide. Since treatment for this disease relies only on the use of praziquantel, there is an urgent need to identify new antischistosomal drugs. Piplartine is an amide alkaloid found in several Piper species (Piperaceae) that exhibits antischistosomal properties. The aim of this study was to evaluate the structure–function relationship between piplartine and its five synthetic analogues (19A, 1G, 1M, 14B and 6B) against Schistosoma mansoni adult worms, as well as its cytotoxicity to mammalian cells using murine fibroblast (NIH-3T3) and BALB/cN macrophage (J774A.1) cell lines. In addition, density functional theory calculations and in silico analysis were used to predict physicochemical and toxicity parameters. Bioassays revealed that piplartine is active against S. mansoni at low concentrations (5⁻10 µM), but its analogues did not. In contrast, based on 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and flow cytometry assays, piplartine exhibited toxicity in mammalian cells at 785 µM, while its analogues 19A and 6B did not reduce cell viability at the same concentrations. This study demonstrated that piplartine analogues showed less activity against S. mansoni but presented lower toxicity than piplartine.Entities:
Keywords: Schistosoma mansoni; analogues; cytotoxicity; piplartine
Mesh:
Substances:
Year: 2018 PMID: 29921756 PMCID: PMC6032158 DOI: 10.3390/ijms19061802
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Electron density: (a) piplartine; (b) 19A; (c) 1G; (d) 14B; (e) 6B and (f) 1M. The colours represent negative (red) and positive (blue). The dipole moments of all compounds in debye values are as follows: piplartine: 5.4728337; 1G: 1.9658996; 1M: 4.4568136; 6B: 4.0062111; 14B: 3.9403826; 19A: 3.7385640.
Figure 2Ultraviolet and visible light absorption spectra of piplartine and its analogues in arbitrary units (A.U.).
Basic, geometric, structural, and solubility parameters of the parent and analogue compounds.
| Compounds | Piplartine | 19A | 14B | 6B | 1M | 1G |
|---|---|---|---|---|---|---|
| Atom count | 40 | 51 | 31 | 48 | 56 | 38 |
| Mw | 315.32 | 287.31 | 432.48 | 387.39 | 239.27 | 359.42 |
| Asymmetric atom count | 0 | 0 | 0 | 0 | 0 | 0 |
| Rotatable bond count | 5 | 6 | 2 | 5 | 7 | 5 |
| Ring count | 2 | 2 | 3 | 3 | 3 | 2 |
| Aromatic ring count | 2 | 1 | 2 | 3 | 3 | 2 |
| Hetero ring count | 1 | 1 | 2 | 0 | 0 | 1 |
| Hydrogen bond donor count | 0 | 0 | 0 | 3 | 1 | 0 |
| Hydrogen bond acceptor count | 5 | 5 | 2 | 5 | 5 | 4 |
| Formal charge | 0 | 0 | 0 | 0 | 0 | 0 |
| Fsp3 (a) | 0.18 | 0.40 | 0.13 | 0.00 | 0.12 | 0.19 |
| Topological polar surface area (A2) | 65.07 | 65.07 | 31.23 | 93.11 | 77.10 | 49.69 |
| Molar refractivity cm3/mol | 87.42 | 101.15 | 70.63 | 112.82 | 123.64 | 79.89 |
| Polarisability (A3) | 32.54 | 38.29 | 26.66 | 41.46 | 46.66 | 30.59 |
| log | 1.89 | 2.71 | 2.36 | 3.55 | 4.63 | 2.26 |
| Milog | 2.19 | 2.78 | 4.69 | 5.02 | 2.86 | 2.90 |
| log | 1.89 | 2.71 | 2.36 | 3.54 | 4.63 | 2.26 |
| Intrinsic solubility | −3.01 | −4.53 | −2.87 | −4.73 | −5.48 | −2.81 |
| Solubility category | High | Moderate | High | Low | Low | High |
| logS pH range 1.7–8.0 | −3.01 | −4.53 | −2.87 | −4.73 | −5.48 | −2.81 |
| Van der Waals volume (Å3) | 281.06 | 337.61 | 213.99 | 341.62 | 390.54 | 260.80 |
| Volume (Å3) (b) | 282.84 | 263.86 | 394.07 | 340.76 | 218.97 | 339.43 |
| Van der Waals surface area (Å2) | 425.62 | 543.27 | 333.75 | 515.78 | 620.14 | 423.69 |
| Solvent accessible surface area (Å2) | 549.15 | 659.24 | 445.82 | 631.17 | 725.57 | 577.96 |
| Topological polar surface area (Å2) | 65.07 | 65.07 | 31.2 | 93.11 | 77.10 | 49.69 |
| Absorbance | 322 nm | 329 nm | 321 nm | 312 nm | 306.5 nm | 301.5 nm |
(a) Number of sp3 carbons/number of carbons; (b) Molinspiration method. 19A, 14B, 6B, 1M, and 1G are analogue compounds of piplartine. Fraction of sp3 carbon atoms (Fsp3).
Toxicity analysis and bioactivity prediction of the parent and analogue compounds against various drug targets.
| Compounds | Piplartine | 19A | 14B | 6B | 1M | 1G | |||
|---|---|---|---|---|---|---|---|---|---|
| AMES toxicity | Yes | No | No | No | No | No | |||
| Max. tolerated dose (human) (0.505 log mg/kg/day) | 1.006 | 0.677 | 1.043 | 1.095 | 1.051 | 1.114 | |||
| hERG I inhibitor | No | No | No | No | No | No | |||
| hERG II inhibitor | No | No | No | Yes | Yes | No | |||
| Oral Rat Acute Toxicity (LD50) (2.661 mol/kg) | 2.268 | 2.295 | 2.413 | 2.195 | 2.37 | 2.389 | |||
| Oral Rat Chronic Toxicity (LOAEL) (3.402 log mg/kg bw/day) | 1.64 | 1.787 | 1.812 | 2.455 | 2.388 | 1.592 | |||
| Hepatotoxicity | No | Yes | No | Yes | Yes | No | |||
| Skin sensitisation | No | No | No | No | No | No | |||
| 1.138 | 1.359 | 2.004 | 0.437 | 0.658 | 1.591 | ||||
| Minnow toxicity (5.577 × log mM) | 1.293 | 0.446 | 1.179 | −0.172 | −0.914 | 1.027 | |||
| GPCR ligand | 0.13 | 0.17 | 0.07 | −0.11 | −0.04 | −0.15 | |||
| Ion channel modulator | −0.51 | −0.16 | −0.53 | −0.27 | −0.29 | −0.54 | |||
| Kinase inhibitor | −0.13 | −0.12 | −0.13 | −0.20 | −0.09 | −0.14 | |||
| Nuclear receptor ligand | −0.32 | −0.07 | −0.12 | −0.31 | −0.30 | −0.31 | |||
| Protease inhibitor | −0.40 | 0.02 | −0.39 | −0.38 | −0.33 | −0.48 | |||
| Enzyme inhibitor | −0.02 | 0.05 | 0.24 | −0.17 | −0.12 | −0.00 | |||
(a) Number of sp3 carbons/number of carbons; (b) Molinspiration method; (c) pkCSM. The Ames test is a widely employed method that uses bacteria to test whether a given chemical can cause mutations in the DNA of the test organism (Ames); The human ether-a-go-go-related gene (hERG); median lethal dose (LD50); Lowest-Observed-Adverse-Effect Level (LOAEL); G-protein-coupled receptors (GPCR).
Figure 3Cytotoxicity evaluation using the MTT method in murine fibroblast (NIH3T3) cells after exposure for 24 h to piplartine analogues (A) 19A (72–2331 μM), (B) 6B (62–1998 μM), (C) 1G (85–2738 μM), (D) 1M (56–1796 μM), (E) 14B (101–3250 μM) and (F) piplartine (78–2514 μM). Molecules were used at the same concentrations range at μg/mL for all samples (25–800). Dimethyl sulfoxide (DMSO) was used as a negative control. The values are expressed as mean ± SEM. * p < 0.05 vs. DMSO control group. The dotted lines mark the 100% viability level.
Determination of pD2 and Emax for the cytotoxic effect of piplartine and its analogues in murine fibroblast (NIH-3T3) cells.
| Compounds | pD2 (−logIC50) a | Emax (%) b |
|---|---|---|
| 19A | −3.06 ± 0.15 | 37.93 ± 2.85 |
| 1G | −2.00 ± 0.03 | 95.69 ± 0.79 |
| 1M | −2.31 ± 0.04 | 70.94 ± 1.20 |
| 14B | −1.95 ± 0.04 | 83.64 ± 0.47 |
| 6B | −2.80 ± 0.08 | 47.93 ± 2.52 |
| Piplartine | 5.68 ± 2.95 | 96.94 ± 0.12 |
a Negative logarithm of the mean inhibitory concentration (IC50); b Emax: decrease in cell viability at the maximum concentration tested (800 μg/mL).
Figure 4Cytotoxicity evaluation in the mouse BALB/cN macrophage (J774A.1) cell line following exposure for 24 h to piplartine analogues (A) 19A (72, 291 and 1165 μM), (B) 6B (62, 249 and 999 μM), (C) 1G (85, 342 and 1369 μM), (D) 1M (56, 224 and 898 μM), (E) 14B (101, 406 and 1625 μM) and (F) piplartine (78, 314 and 1257 μM). Molecules were used at the same concentrations range at μg/mL for all samples (25, 100 and 400). Dulbecco’s Modified Eagle Medium (DMEM) was used as a negative control. Cells were analysed by flow cytometry (20,000 events/sample). The values are expressed as mean ± SEM. * p < 0.05 and **** p < 0.0001 vs. DMEM control group.
Figure 5Evaluation of the cell death mechanism mediated by (A) piplartine (78, 314 and 1257 μM) and its analogues (B) 1G (85, 342 and 1369 μM), (C) 1M (56, 224 and 898 μM), (D) 6B (62, 249 and 999 μM), (E) 14B (101, 406 and 1625 μM) and (F) 19A (72, 291 and 1165 μM) in J774A.1 cells following treatment for 24 h at the same concentrations range at μg/mL for all samples (25, 100 and 400) using annexin-V FITC (apoptosis marker) and propidium iodide (PI, necrosis marker) staining. Cells were analysed by flow cytometry (20,000 events/sample). The values are expressed as mean ± SEM. * p < 0.05 vs. DMEM untreated control group. # p < 0.05 vs. apoptosis staining from each respective group.
In vitro effects of compounds in 49-day-old S. mansoni worms.
| Group | Period of Incubation (h) | Dead Worms (%) a | Motor Activity Reduction (%) a | ||||
|---|---|---|---|---|---|---|---|
| Slight | Significant | ||||||
| M | F | M | F | M | F | ||
| Control b | 24 | 0 | 0 | 0 | 0 | 0 | 0 |
| 48 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 72 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 96 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 0.5% DMSO | 24 | 0 | 0 | 0 | 0 | 0 | 0 |
| 48 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 72 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 96 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Praziquantel | 24 | 100 | 100 | 0 | 0 | 100 | 100 |
| 2 µM | 48 | 100 | 100 | 0 | 0 | 100 | 100 |
| 72 | 100 | 100 | 0 | 0 | 100 | 100 | |
| 96 | 100 | 100 | 0 | 0 | 100 | 100 | |
| Amide piplartine | 24 | 100 | 100 | 0 | 0 | 100 | 100 |
| 10 µM | 48 | 100 | 100 | 0 | 0 | 100 | 100 |
| 5 µM | 72 | 100 | 100 | 0 | 0 | 100 | 100 |
| 96 | 100 | 100 | 0 | 0 | 100 | 100 | |
| 24 | 0 | 0 | 100 | 100 | 0 | 0 | |
| 48 | 0 | 0 | 100 | 100 | 0 | 0 | |
| 72 | 0 | 0 | 100 | 100 | 0 | 0 | |
| 96 | 60 | 60 | 0 | 0 | 60 | 60 | |
a Percentages relative to the 20 worms investigated; b RPMI 1640. The effect of the compounds on motor activity of adult S. mansoni was assessed qualitatively. Male (M) and Female (F).